Curatis Holding AG (SWX:CURN)

Market Cap	115.97M +121.2%
Revenue (ttm)	10.80M +56.6%
Net Income	-1.42M
EPS	-0.28
Shares Out	5.15M
PE Ratio	n/a
Forward PE	1.34
Dividend	n/a
Ex-Dividend Date	n/a

Volume	282
Average Volume	3,868
Open	21.50
Previous Close	21.60
Day's Range	21.10 - 22.50
52-Week Range	9.14 - 27.90
Beta	-1.06
RSI	57.57
Earnings Date	Apr 9, 2026

About Curatis Holding AG

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson’s disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collage...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Roland Rutschmann
• Employees: 9
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: CURN

Financial Performance

In 2025, Curatis Holding AG's revenue was 10.80 million, an increase of 56.61% compared to the previous year's 6.90 million. Losses were -1.42 million, -67.41% less than in 2024.